Mark Frohlich, Founder of Indapta Therapeutics

Mark Frohlich is the founder of Indapta Therapeutics. Indapta Therapeutics has raised $73M in total funding. Latest round: Series A.

About Mark Frohlich

Mark W. Frohlich, M.D. is the Chief Executive Officer of Indapta Therapeutics, a privately held biotechnology company developing an NK cell therapy platform for blood and solid tumor cancers. Indapta announced his appointment as CEO in February 2022 alongside its Series A financing. He previously served as executive vice president of portfolio strategy at Juno Therapeutics and was chief medical officer and executive vice president at Dendreon Corporation.

Mark Frohlich at a glance

More founders in San Francisco, United States (44)

Browse related founder lists (6)

Full founder directory · Investor directory · Company funding database · Fundraising library